PT - JOURNAL ARTICLE AU - Mayank Batra AU - Runxia Tian AU - Chongxu Zhang AU - Emile Clarence AU - Camila Sofia Sacher AU - Justin Nestor Miranda AU - Justin Rafa O De La Fuente AU - Megan Mathew AU - Desmond Green AU - Sayari Patel AU - Maria Virginia Perez Bastidas AU - Sara Haddadi AU - Mukunthan Murthi AU - Miguel Santiago Gonzalez AU - Shweta Kambali AU - Kayo H M Santos AU - Huda Asif AU - Farzaneh Modarresi AU - Mohammad Faghihi AU - Mehdi Mirsaeidi TI - Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes AID - 10.1101/2020.09.23.20197251 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.23.20197251 4099 - http://medrxiv.org/content/early/2020/09/24/2020.09.23.20197251.short 4100 - http://medrxiv.org/content/early/2020/09/24/2020.09.23.20197251.full AB - The Nucleocapsid Protein (N Protein) of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) is located in the viral core. Immunoglobulin G (IgG) targeting N protein is detectable in the serum of infected patients. The effect of high titers of IgG against N-protein on clinical outcomes of SARS-CoV2 disease has not been described. We studied 400 RT-PCR confirmed SARS-CoV2 patients to determine independent factors associated with poor outcomes, including MICU admission, prolonged MICU stay and hospital admissions, and in-hospital mortality. We also measured serum IgG against the N protein and correlated its concentrations with clinical outcomes. We found that several factors, including Charlson comorbidity Index (CCI), high levels of IL6, and presentation with dyspnea were associated with poor clinical outcomes. It was shown that higher CCI and higher IL6 levels were independently associated with in-hospital mortality. Anti-N protein IgG was detected in the serum of 55 (55%) patients at the time of admission. A high concentration of antibodies, defined as signal to cut off ratio (S/Co)> 1.5 (75 percentile of all measurements), was found in 25 (25%) patients. The multivariable logistic regression models showed that between being an African American, higher CCI, lymphocyte counts, and S/Co ratio> 1.5, only S/Co ratio were independently associated with MICU admission and longer length of stay in hospital. This study recommends that titers of IgG targeting N-protein of SARS-CoV2 at admission is a prognostic factor for the clinical course of disease and should be measured in all patients with SARS-CoV2 infection.Competing Interest StatementDr. Farzaneh Modarresi and Dr. Mohammad Faghihi are employees of Gene Express. Other authors have no conflict of interest to disclose. Funding StatementThis study was partially supported by a research donation from Paige Family.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (IRB) of the University of Miami.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request from the authors.